Clinical Scorecard: ten23 health and BD Partner to Address Demand for Self-Administered Therapies
At a Glance
| Category | Detail |
|---|---|
| Condition | Self-Administered Therapies |
| Key Mechanisms | Subcutaneous delivery of large-volume drugs using wearable injectors. |
| Target Population | Patients requiring high-dose biologics. |
| Care Setting | Outpatient and home care settings. |
Key Highlights
- Collaboration supports commercialization of BD Libertas™ wearable injector.
- Enables subcutaneous delivery of high-volume biologics.
- Facilitates faster development and reduces risks in injectable programs.
- Includes process development, aseptic filling, and quality control services.
- Line 0 allows testing and optimization without GMP production delays.
Guideline-Based Recommendations
Diagnosis
Management
- Utilize BD Libertas™ for efficient subcutaneous administration of biologics.
Monitoring & Follow-up
Risks
- Consider potential challenges in transitioning from IV to SC delivery.
Patient & Prescribing Data
Patients requiring high-dose biologics for chronic conditions.
Wearable injectors may enhance patient experience and adherence.
Clinical Best Practices
- Leverage integrated services for supply chain readiness.
- Conduct stability studies and optimize processes under representative conditions.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
